Biogen Announces Collaborations to Develop Treatments for Neurological Disorders

Biogen, a New England Council member, has announced two major partnerships with Boston-area biotech groups. It will partner with C4 Therapeutics in a collaborative effort to discover and develop potential new treatments for neurological conditions, such as Alzheimer’s and Parkinson’s. In addition, Biogen has announced an arrangement with Skyhawk Therapeutics.

While Biogen already has several Alzheimer’s drugs in development, these two collaborative arrangements will enhance its ability to tackle the challenges of more central nervous system diseases. Under the agreement with C4T, Biogen will provide neuroscience expertise and drug development capabilities, and C4T will provide expertise and research services. The arrangement with Skyhawk Therapeutics differs, with Biogen responsible for funding Skyhawk Therapeutic’s development of treatments for multiple sclerosis, spinal muscular atrophy, and other neurological disorders.

Michael Ehlers, M.D., Ph.D., Executive Vice President of Research and Development at Biogen said, “This new collaboration with C4T complements our broader research strategy to develop potential therapies for neurological conditions across multiple modalities. We look forward to discovering new potential therapeutic options for diseases that currently have limited-to-no treatment options available.”

The New England Council applauds Biogen’s collaborative efforts in researching and developing cutting-edge treatments targeting Alzheimer’s and other serious neurological disorders.

Read more from the Boston Business Journal.

img_side
mask_sidebar
Recently from the Blog

Liberty Mutual Gives Boston Homelessness Nonprofit Largest-Ever Grant

10/27/2021 | Read Post

Bank of America Raises Minimum Wage to $21, Plans for $25 by 2025

10/27/2021 | Read Post

In the News

NEC to Honor Historic All-Female Lineup of 2021 New Englanders of the Year

08/2/2021 | Read Press Release

NEC Board Elects Three New Directors

04/27/2021 | Read Press Release